RxDoctor Payments Data

Heather Skeens, MD

Ophthalmology · South Charleston, WVNPI 1770520439

Payments from drug & device makers

What this record shows

This record is dominated by other: $5,378 of the $5,859 with a category attached, or 91.8%. Alcon accounts for 94.2% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2023 at $5,511 and has fallen 98.8% since, to $64 in 2025.

$5,859in general payments, 2019–2025

Across 25 payments — averaging $234.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$6K
  • AbbVie$126
  • Sun Pharmaceutical Industries Inc.$63
  • Shire North American Group Inc$42
  • Bausch & Lomb Americas Inc.$29
  • Ocular Therapeutix, Inc.$28
  • plus $49 from 3 others

What the payments were for

  • Food & beverage$4618%
  • Gifts$190%
  • Other$5,37892%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,859 in reported general payments places this provider in the 85th percentile of 85 ophthalmology providers in West Virginia.

See all ophthalmology providers in West Virginia

Medicare billing

Part B allowed, 2024
$226,637
Medicare patients
364
Services billed
1,518

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine234$188,374
Prednisolone Acetate849$36,754
Loteprednol Etabonate223$35,335
Cyclosporine85$34,124
XiidraLifitegrast29$22,454
Lotemax SmLoteprednol Etabonate40$12,097
Difluprednate96$10,123
MoxifloxacinMoxifloxacin Hcl414$8,652
Ketorolac Tromethamine313$7,293
Dorzolamide-TimololDorzolamide/Timolol/Pf31$7,256
Fluorometholone41$4,745
ValacyclovirValacyclovir Hcl143$3,910
LumiganBimatoprost11$3,576
Travoprost23$3,065
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat131$2,138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$126$191,949245 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Lotemax Sm$14$47,432263 claims
Bausch & Lomb Americas Inc.Xiidra$29$22,45429 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 85 ophthalmology providers in West Virginia.

Other ophthalmology in South Charleston

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →